Mereo BioPharma vs Rallybio
MREO and RLYB side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How MREO and RLYB compare
Mereo BioPharma is the larger company, worth 2.7 times as much as Rallybio ($219M against $82.3M).
Rallybio scores higher on the StockData Score (10 against 1 for Mereo BioPharma), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | MREO | RLYB |
|---|---|---|
| Size and price | ||
| Market cap | $219M | $82.3M |
| Share price | $0.275 | $15.29 |
| Change, 1 year | −84.6% | 199% |
| Change, 5 years | −85.6% | −85.5% |
| Beta (5Y) | 2.29 | 0.01 |
| Employees | 39 | 14 |
| StockData Score | ||
| Total score | 1 | 10 (better) |
| Valuation score | 0 | 2 (better) |
| Growth score | 0 | 0 |
| Performance score | 0 | 2 (better) |
| Health score | 1 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | – | 3.4× |
| P/S | – | 190× |
| P/B | 9.2× | 0.9× (better) |
| FCF yield | −10.1% | – |
| Growth | ||
| Revenue growth (TTM) | – | −35.6% |
| Profitability | ||
| Operating margin | – | −5581% |
| Net margin | – | 6177% |
| Return on equity | −76.6% | 34.5% (better) |
| Return on invested capital | – | −718% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −440.6× | – |
| Current ratio | 5.22 | 28.87 (better) |
| Altman Z-score | −4.68 | 11.42 (better) |
| Piotroski F-score | 4 | 4 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 7.1% | – |
| Held by insiders | 0.18% | 72.6% |
| Insider net buying, 12 months | – | $4.2M |
| Superinvestors holding | – | 1 |
| Short interest, % of float | – | 2.6% |
Go deeper
- MREO stock overview
- MREO income statement
- MREO valuation and score
- RLYB stock overview
- RLYB income statement
- RLYB valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.